GENEVA, Switzerland and NEW YORK CITY, United States of America, July, 15, 2026 – FIND has announced the launch of ACCEDE 2.0 (Access to CGMs for Equity in Diabetes Management), a new phase of the collaboration to expand access to continuous glucose monitoring (CGM) technologies for people living with diabetes in low- and middle-income countries (LMICs). The program is supported by a $3.2 Million USD grant from The Leona M. and Harry B. Helmsley Charitable Trust.
Building on work undertaken in Kenya and South Africa, ACCEDE 2.0 will expand to India and additional countries in Africa and Southeast Asia as government agreements are finalized. Running from 2026 to 2029, the program will use evidence, partnerships, and implementation experience from the first phase to support broader, more sustainable access to CGMs.
ACCEDE 2.0 will work with governments, healthcare providers, diabetes organizations, manufacturers, funders, and people with lived experience to advance equitable CGM access through evidence generation, improved market health, capacity strengthening, and policy engagement.
The project will help countries address persistent barriers to CGM access, including affordability, awareness, health system readiness, and sustainable financing.
“Access to modern diabetes technologies should not depend on where a person lives,” said Dr Priyanka Singh, Head of NCDs, FIND. “ACCEDE 2.0 represents an important step towards ensuring that people living with diabetes in LMICs can benefit from the same advances in care that are transforming outcomes elsewhere.”
Diabetes is one of the fastest-growing health burdens worldwide. The International Diabetes Federation’s 2025 Diabetes Atlas estimates that 589 million adults, nearly 1 in 9 people (20-79 years) are living with diabetes globally, with over four in five adults with diabetes living in LMICs. ACCEDE 2.0 responds to this gap by supporting country-led approaches so that people most affected are not the last to benefit from advances in diabetes care. CGM is now the standard of care in high-income countries for people with type 1 diabetes and increasingly for those with type 2 diabetes.
Building on evidence and experience
Since 2023, ACCEDE has supported CGM access in Kenya and South Africa, through evidence generation, stakeholder engagement, capacity strengthening, and initiatives to improve market health.
Key achievements of the first phase include:
ACCEDE 2.0 will translate these lessons into action at greater scale and across a broader range of country contexts.
Expanding the pathway to access
ACCEDE 2.0 will focus on:
James Reid, Program Officer, Type 1 Diabetes at the Helmsley Charitable Trust said: “By expanding this work to additional countries, ACCEDE 2.0 seeks to accelerate sustainable and affordable CGM access models that can be adapted and scaled across low- and middle-income countries.”
Although CGMs are now central to diabetes management in many high-income settings, access remains limited in much of the world. ACCEDE 2.0 aims to help close this gap by supporting evidence-based, country-led pathways to adoption and improved diabetes outcomes.
About FIND
FIND accelerates equitable access to reliable diagnosis around the world. We are working to close critical testing gaps that leave people at risk from preventable and treatable illnesses, enable effective disease surveillance, and build sustainable, resilient health systems. In partnership with countries, WHO and other global health agencies, we are driving progress towards global health security and universal health coverage. We are a WHO Collaborating Centre for Laboratory Strengthening and Diagnostic Technology Evaluation. For more information, please visit www.finddx.org
About The Leona M. and Harry B. Helmsley Charitable Trust
The Leona M. and Harry B. Helmsley Charitable Trust aspires to improve lives by supporting exceptional efforts in the U.S. and around the world in health and select place-based initiatives. Since beginning active grantmaking in 2008, Helmsley has granted more than $4.6 billion for a wide range of charitable purposes. The Helmsley Type 1 Diabetes (T1D) Program is the largest private foundation funder in the world with a focus on T1D, with more than $1.3 billion to date committed to transform the trajectory of the disease and to accelerate access to 21st century care, everywhere. For more information on Helmsley and its programs, visit www.helmsleytrust.org.
Media Contacts
FIND
Dorcas Mapondera
Chief of Staff/Head External Affairs
media@finddx.org
Helmsley Charitable Trust
Alison Carley
Communications Officer
acarley@helmsleytrust.org
